CVRx preliminary Q1 revenue rises 20%, gross margin improves

CVRx

13/04/2026 13:11

Overview

U.S. medical devices maker's preliminary Q1 2026 revenue up about 20% yr/yr

Preliminary Q1 gross margin expected to rise to 87% from 84% a year ago

Company cites investments and improved CPT code reimbursement for revenue growth

Outlook

Company expects enrollment in BENEFIT-HF trial to begin in Q2 2026

Early 2026 data shows 30-day Medicare Advantage prior authorization approval rate at 50%

Result Drivers

IMPROVED REIMBURSEMENT - Co said adoption of Category I CPT code for Barostim led to higher prior authorization approval rates and more predictable reimbursement

INVESTMENTS IN TEAM AND PROGRAMS - Co said investments made in 2025 contributed to Q1 2026 revenue growth, per CEO Kevin Hykes

Company press release: ID:nGNX62vjf4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Gross Margin
87.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

Wall Street's median 12-month price target for CVRx Inc is $12.00, about 67.7% above its April 10 closing price of $7.16

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)